阅读说明：本技术 一种调节婴幼儿肠道短链脂肪酸代谢的组合物及其应用 (Composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof ) 是由 刘斐童 王园园 胡瑞标 陈桔淳 郑雨星 赵飞 彭倩 于 2021-06-15 设计创作，主要内容包括：本发明公开了一种调节婴幼儿肠道短链脂肪酸代谢的组合物,包含以下组分：乳铁蛋白3～6重量份、动物双歧杆菌粉0.3～1重量份和低聚半乳糖40～60重量份；所述动物双歧杆菌粉中含有动物双歧杆菌10～(7)～10～(8)CFU/重量份。本发明所述组合物采用乳铁蛋白、动物双歧杆菌和低聚半乳糖三者复配能够增加婴幼儿肠道短链脂肪酸总含量和乙酸含量,有利于调节婴幼儿肠道短链脂肪酸代谢,可应用于制备具有调节婴幼儿肠道短链脂肪酸代谢功能、增加肠道短链脂肪酸含量或增加肠道乙酸含量的药物或食品。(The invention discloses a composition for regulating the metabolism of infant intestinal short-chain fatty acid, which comprises the following components: 3-6 parts of lactoferrin, 0.3-1 part of animal bifidobacterium powder and 40-60 parts of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 10 7 ～10 8 CFU/part by weight. The composition disclosed by the invention can increase the total content of infant intestinal short-chain fatty acids and the content of acetic acid by compounding lactoferrin, bifidobacterium animalis and galactooligosaccharides, is beneficial to adjusting the metabolism of the infant intestinal short-chain fatty acids, and can be applied to preparation of medicines or foods with the functions of adjusting the metabolism of the infant intestinal short-chain fatty acids, increasing the content of the intestinal short-chain fatty acids or increasing the content of the intestinal acetic acid.)

1. A composition for regulating the metabolism of short chain fatty acids in the infant's intestinal tract, comprising the following components: 3-6 parts of lactoferrin, 0.3-1 part of animal bifidobacterium powder and 40-60 parts of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 10⁷～10⁸CFU/part by weight.

2. The composition for modulating the metabolism of infant intestinal short chain fatty acids according to claim 1, wherein the composition comprises the following components: 5.5 parts by weight of lactoferrin, 0.5 part by weight of animal bifidobacterium powder and 50 parts by weight of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 10⁷～10⁸CFU/part by weight.

3. Use of the composition for regulating the metabolism of infant intestinal short-chain fatty acids according to claim 1 or 2 for preparing a medicament or food with the function of regulating the metabolism of infant intestinal short-chain fatty acids.

4. The use according to claim 3, wherein the food product is a reconstituted milk powder, a nutraceutical or a beverage product.

5. Use of a composition for modulating the intestinal short chain fatty acid metabolism in infants and young children according to claim 1 or 2 for the manufacture of a medicament or food product having an increased intestinal short chain fatty acid content or an increased intestinal acetic acid content.

6. The use of claim 5, wherein the food product is a reconstituted milk powder, a nutraceutical, or a beverage product.

7. Modified milk powder comprising a composition for modulating the metabolism of short chain fatty acids in the infant's intestine according to claim 1 or 2.

8. The modified milk powder of claim 7, wherein the composition for regulating the metabolism of infant intestinal short chain fatty acids is present in the modified milk powder in an amount of 3 to 6% by weight.

Technical Field

The invention relates to the field of food, and in particular relates to a composition for regulating infant intestinal tract short-chain fatty acid metabolism and application thereof.

Background

The intestinal flora coexists with the body and exerts a great deal of influence on the body in the aspects of metabolism, development and maturation of immune function, protection of intestinal tract and the like. The effects on the metabolism of the body, such as the production of short-chain fatty acids, mainly acetate, propionate and butyrate, can provide energy and maintain the growth and development of the gastrointestinal tract, and are very important for the intestinal health of infants. Some intestinal flora may synthesize vitamins, such as vitamin K and other vitamin B groups, that have important effects on infants. Some bacteria in the intestinal tract can also produce conjugated linoleic acid, which plays an important role in the normal growth and development of newborns, and is associated with obesity, diabetes and immune function. The gut flora may also influence the blood concentration of tryptophan, an essential amino acid, by the kynurenine pathway, which is important in the development of the central nervous system. The interaction between the intestine and the brain forms a brain-intestine axis, and integrates the mechanisms of nerve, immunity and endocrine, while the intestinal flora can play a role similar to signal molecules in the brain-intestine axis and play a role in regulating various aspects such as immune function, central nervous system and gastrointestinal function in the early life. The intestinal flora can influence the colonization and reproduction of pathogenic bacteria through biological antagonism, thereby protecting organisms from being damaged by the pathogenic bacteria. The intestinal bacteria have regulating effect on both innate immunity and adaptive immunity. Through aseptic animal experimental studies, it has been demonstrated that intestinal microorganisms are essential for maintaining normal intestinal morphology and immune maturation, and mice that survive aseptic conditions exhibit impaired development of the intestinal immune system and a defect in oral immune tolerance. Bifidobacteria in the recombinant gut flora may restore the oral tolerance during neonatal period.

Intestinal microorganisms are an important part of the human body and play a very important role in the development, function and regulation of the human immune system in various ways from birth. The evolutionary symbiotic relationship between humans and intestinal microorganisms has numerous benefits to humans, including regulation of host immunity, production of vitamin K and vitamin B, protection of the gut from pathogens, enhancement of gut integrity, and production of Short Chain Fatty Acids (SCFAs), metabolites. Short chain fatty acids are produced by intestinal flora by fermenting carbohydrates, mainly acetic acid, propionic acid, butyric acid, etc. Short Chain Fatty Acids (SCFA) mediate the interaction between gut flora and host metabolism, and the effects of both prebiotics and probiotics depend on SCFA. Short chain fatty acids are thought to mediate communication between the gut flora and the immune system, inhibiting the proliferation of certain bacteria by lowering the pH of the gut, and are critical to gut homeostasis. SCFAs can conduct signals through G protein sensitive G protein coupled receptors, and SCFAs circulating in blood can affect tissue specific acetylation of histones 3 and 4, and induce epigenetic change of genome; the content of SCFAs in intestinal tracts is increased through special diet, so that the diabetes of non-obese diabetic mice can be prevented; during pregnancy, SCFAs can cause epigenetic imprints in the uterus and prevent allergic diseases in the infant's airways; SCFAs also regulate blood brain barrier and neuroimmune endocrine function. Short chain fatty acids can inhibit Histone Deacetylases (HDACs), which are involved in regulating gene expression in many diseases and promoting the onset of disease. SCFAs play a beneficial role in the metabolism and function of adipose tissue, skeletal muscle and liver stroma and contribute to improved insulin sensitivity.

Acetate, propionate, butyrate are the major SCFAs, and lactate, succinate are precursors of SCFAs, produced mediated by specific intestinal microbial enzymes, at concentrations that are highest in the cecum and proximal colon, and are a source of colonic cellular energy. Animal and human data suggest that acetate affects host energy and substrate metabolism by regulating intestinal hormone secretion and metabolism substrates such as glucagon-like peptide-1 and peptide YY. Appetite is affected by reducing systemic lipolysis, levels of systemic inflammatory cytokines, increasing energy expenditure and fat oxidation. Acetate may also be produced by deacetylation of endogenous proteins, such as histones. Acetate plays a key role in maintaining intracellular levels of acetyl-coa, and disturbances in acetate metabolism are associated with several human diseases. Short Chain Fatty Acid (SCFA) produced by fermenting dietary fiber by intestinal flora has immunoregulation function.

There is currently no study on compositions that increase the content of short chain fatty acids in the infant's intestinal tract.

Disclosure of Invention

The invention aims to overcome the defects in the prior art and provide a composition for regulating the metabolism of short-chain fatty acids in the intestinal tract of infants and application thereof.

In order to achieve the purpose, the invention adopts the technical scheme that: a composition for regulating the metabolism of short chain fatty acids in the infant's intestinal tract, comprising the following components: 3-6 parts of lactoferrin, 0.3-1 part of animal bifidobacterium powder and 40-60 parts of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 10⁷～10⁸CFU/part by weight.

The inventor finds that the composition disclosed by the invention can increase the total content of infant intestinal short-chain fatty acids and the content of acetic acid by compounding lactoferrin, bifidobacterium animalis and galactooligosaccharides, and is beneficial to regulating the metabolism of the infant intestinal short-chain fatty acids.

Preferably, the composition comprises the following components: 5.5 parts by weight of lactoferrin, 0.5 part by weight of animal bifidobacterium powder and 50 parts by weight of galacto-oligosaccharide; the animal bifidobacterium powder contains animal bifidobacterium 10⁷～10⁸CFU/part by weight. The effect of increasing the total content of short chain fatty acid and the content of acetic acid in the intestinal tract of the infant by matching the three components in the proportion is better than that of two or one of the three components.

The invention also aims to provide the application of the composition for regulating the metabolism of the infant intestinal short-chain fatty acid in preparing a medicament or food with the function of regulating the metabolism of the infant intestinal short-chain fatty acid; preferably, the food is prepared milk powder, health-care products or drinks.

The invention also aims to provide application of the composition for regulating the intestinal short-chain fatty acid metabolism of infants in preparing medicines or foods with the function of increasing the intestinal short-chain fatty acid content or increasing the intestinal acetic acid content. Preferably, the food is prepared milk powder, health-care products or drinks.

The invention also aims to provide the modified milk powder, which comprises the composition for regulating the metabolism of the short-chain fatty acid in the intestinal tract of the infant.

Preferably, the weight percentage of the composition for regulating the metabolism of the infant intestinal short-chain fatty acid in the modified milk powder is 3-6%. When the composition is added into prepared milk powder, the metabolism of short-chain fatty acids in the intestinal tract of infants can be effectively regulated, and the intestinal health is maintained.

The invention has the beneficial effects that: the composition is prepared by compounding lactoferrin, animal bifidobacteria and galactooligosaccharides, can increase the total content of short-chain fatty acids and the content of acetic acid in the intestinal tract of infants, is favorable for adjusting the metabolism of the short-chain fatty acids in the intestinal tract of infants, and can be applied to preparation of medicines or foods with the functions of adjusting the metabolism of the short-chain fatty acids in the intestinal tract of infants, increasing the content of the short-chain fatty acids in the intestinal tract or increasing the content of the acetic acid in the intestinal tract.

Drawings

FIG. 1 is a graph showing the acetate content in a sample;

FIG. 2 is a graph showing the total short chain fatty acid content in the samples.

Detailed Description

To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.

The sources of the raw materials are as follows:

galacto-oligosaccharide: DP2-DP8, available from Quantum Kogaku;

lactoferrin: purchased from warranwood warenburg;

animal bifidobacterium powder: BB12 from Kehansen.

10 infants of 0-6 months are recruited in a company, the information such as the diet condition of the infants, the using condition of probiotics and the like is investigated, and 4 volunteers meeting the experimental requirements are selected from the information: feeding with pure breast milk, adding no supplementary food, preventing diarrhea or constipation in one month, and collecting feces samples after filling informed consent without using probiotics, medicine and antibiotics.

Three test groups were set:

1. galacto-oligosaccharides (GOS) group: 50mg of galacto-oligosaccharide;

2. lactoferrin + bifidobacterium animalis (LF + BB12) group: 5.5Lactoferrin and 0.5mg Bifidobacterium animalis powder (containing Bifidobacterium animalis 10. mu.m. in it)⁷CFU)；

3. Lactoferrin + bifidobacterium animalis + galactooligosaccharides (LF + BB12+ GOS) group: 5.5mg of lactoferrin, 0.5mg of animal bifidobacterium powder (containing about bifidobacterium animalis 10 therein)⁷CFU) and 50mg galacto-oligosaccharide.

Preparing a trace element solution: scale FeSO₄·7H₂O 3.68g、MnSO_4·H₂O 1.159g、ZnSO_4·7H₂O 0.44g、CoCl_2·6H₂O 0.12g、NiCl₂ 0.10g、CuSO_4·5H₂O0.098 g and Mo₇(CH₄)₆O₂₄H₂O0.017 g, dissolved in 1L of sterile water.

Preparing a buffer solution: MgCl₂·6H₂O 0.1g、NaSO₄ 0.1g、CaCl₂·2H₂0.728g of O, 0.4g of urea, 0.45g of KCl, 0.47g of NaCl and Na₂HPO₄ 2.824g、NaHCO₃9.24g of the mixture, 0.001mg of the Resazurin and 10ml of the trace element solution are mixed, the volume is determined to be 1L, and the mixture is sterilized for later use.

The excrement sample is tested one by one, firstly, the excrement sample is filtered, and the prepared buffer solution and the sample are added: buffer 1: 4, preparing the excrement homogenate. Taking 1ml of excrement homogenate to be filled into fermentation vials containing different raw materials, adding 3ml of buffer solution, covering the caps, and then carrying out anaerobic fermentation at 37 ℃. During the fermentation, the amount of short chain fatty acid was measured by gas phase at 4h, 8h,24h, and 48h, and the test results are shown in tables 1 and 2 and fig. 1 and 2.

TABLE 1 acetate content in the samples (unit: mmol/L)

Time	GOS	LF+BB12	LF+BB12+GOS
				4h	15.29±12.95	7.25±3.90	31.09±15.85
8h	35.19±30.25	9.55±4.12	52.66±34.70
				24h	51.14±24.33	15.95±3.56	76.68±31.73
48h	51.66±22.25	27.27±11.47	85.84±19.73

TABLE 2 Total short chain fatty acid content (unit: mmol/L) in the samples

Time	GOS	LF+BB12	LF+BB12+GOS
				4h	16.20±13.11	7.56±4.10	29.12±13.15
8h	36.23±1.840	10.84±4.38	60.06±2.291
				24h	51.43±2.674	19.71±4.50	80.23±3.120
48h	57.72±1.569	33.69±13.48	92.42±1.469

From tables 1 and 2 and fig. 1 and 2, it can be seen that the addition of GOS significantly increased the level of intestinal acetic acid over time by fermentation with the intestinal flora of pure breast-fed infants. The lactoferrin + bifidobacterium animalis + galacto-oligosaccharides (LF + BB12+ GOS) group started at 8h and produced higher total short chain fatty acids than the GOS group and LF + BB12 group, and than the sum of the other two groups, with significant differences, and also significantly higher at 24h and 48h than the other groups. Therefore, the composition can improve the generation amount of total short-chain fatty acid in the in-vitro simulated fermentation process, and can balance the content of key fatty acid metabolites such as acetic acid, propionic acid and butyric acid in the intestinal tracts of infants. Short chain fatty acids can lower the pH of the intestinal tract to inhibit proliferation of certain bacteria; the acetate has anticancer effect and can improve intestinal function. It can therefore be assumed that a composition comprising lactoferrin, galactooligosaccharides and bifidobacterium animalis is beneficial for healthy development of the infant's gut.

Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.